634 related articles for article (PubMed ID: 26041461)
1. Potential relationship between Hashimoto's thyroiditis and BRAF(V600E) mutation status in papillary thyroid cancer.
Zeng RC; Jin LP; Chen ED; Dong SY; Cai YF; Huang GL; Li Q; Jin C; Zhang XH; Wang OC
Head Neck; 2016 Apr; 38 Suppl 1():E1019-25. PubMed ID: 26041461
[TBL] [Abstract][Full Text] [Related]
2. Combined effect of Hashimoto's thyroiditis and BRAF(V600E) mutation status on aggressiveness in papillary thyroid cancer.
Kim SJ; Myong JP; Jee HG; Chai YJ; Choi JY; Min HS; Lee KE; Youn YK
Head Neck; 2016 Jan; 38(1):95-101. PubMed ID: 25213729
[TBL] [Abstract][Full Text] [Related]
3. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
[TBL] [Abstract][Full Text] [Related]
4. Integrating BRAF
Zhang Z; Zhang X; Yin Y; Zhao S; Wang K; Shang M; Chen B; Wu X
BMC Cancer; 2022 Apr; 22(1):461. PubMed ID: 35473554
[TBL] [Abstract][Full Text] [Related]
5. Correlation Between the Clinicopathological Features of Papillary Thyroid Carcinoma Complicated with Hashimoto's Thyroiditis, BRAF V600E Gene Mutation, and RET Gene Rearrangement.
Xie M; Xu ZX; Dai M; Zhu YY
J Coll Physicians Surg Pak; 2024 Apr; 34(4):445-450. PubMed ID: 38576288
[TBL] [Abstract][Full Text] [Related]
6. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
7. [Association between BRAF V600E mutation and central lymph node metastasis in patients with papillary thyroid carcinoma].
Shi C; Qin H; Ding C; Sun Y; Lyu Y; Shi T
Zhonghua Zhong Liu Za Zhi; 2015 Feb; 37(2):123-7. PubMed ID: 25975689
[TBL] [Abstract][Full Text] [Related]
8. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 Jan; 23(1):27-34. PubMed ID: 26598713
[TBL] [Abstract][Full Text] [Related]
9. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
[TBL] [Abstract][Full Text] [Related]
10. Association Between BRAF
Shangguan R; Hu YP; Huang J; Yang SJ; Ye L; Lin RX; Zhu J; Zhang TL; Ying L; Li P
Acad Radiol; 2019 Feb; 26(2):154-160. PubMed ID: 29941398
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of FNAC combined with BRAF
Fu J; Yin X; Wang X; Xiao S; Wu X; Duan C; Yu W; Zhang G
Front Endocrinol (Lausanne); 2024; 15():1366724. PubMed ID: 38818506
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and Impact of BRAF mutation in patients with concomitant papillary thyroid carcinoma and Hashimoto's thyroiditis: a systematic review with meta-analysis.
Janicki L; Patel A; Jendrzejewski J; Hellmann A
Front Endocrinol (Lausanne); 2023; 14():1273498. PubMed ID: 38047109
[TBL] [Abstract][Full Text] [Related]
13. The synergic effect of BRAF
Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
[TBL] [Abstract][Full Text] [Related]
14. BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto's thyroiditis lymphocytic infiltration is present.
Marotta V; Guerra A; Zatelli MC; Uberti ED; Di Stasi V; Faggiano A; Colao A; Vitale M
Clin Endocrinol (Oxf); 2013 Nov; 79(5):733-8. PubMed ID: 23469895
[TBL] [Abstract][Full Text] [Related]
15. BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma.
Ahn D; Park JS; Sohn JH; Kim JH; Park SK; Seo AN; Park JY
Auris Nasus Larynx; 2012 Apr; 39(2):198-203. PubMed ID: 21862261
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
[TBL] [Abstract][Full Text] [Related]
17. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
[TBL] [Abstract][Full Text] [Related]
18. Association between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and without Hashimoto's Thyroiditis.
Zhang Q; Liu BJ; Ren WW; He YP; Li XL; Zhao CK; Zhang YF; Yue WW; Zheng JY; Xu HX
Sci Rep; 2017 Jul; 7(1):4899. PubMed ID: 28687736
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for central lymph node metastasis in patients with papillary thyroid carcinoma: a retrospective study.
Du J; Yang Q; Sun Y; Shi P; Xu H; Chen X; Dong T; Shi W; Wang Y; Song Z; Shang X; Tian X
Front Endocrinol (Lausanne); 2023; 14():1288527. PubMed ID: 38047112
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center.
Lim JY; Hong SW; Lee YS; Kim BW; Park CS; Chang HS; Cho JY
Thyroid; 2013 Nov; 23(11):1423-30. PubMed ID: 23496275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
